John J. Trizzino

Executive Vice President, Chief Commercial Officer & Chief Business Officer at Novavax, Inc.

John J. Trizzino

John J. Trizzino

Executive Vice President, Chief Commercial Officer & Chief Business Officer at Novavax, Inc.

Overview
Career Highlights

IMV, Inc.

RelSci Relationships

1234

Number of Boards

2

Birthday

1960

Age

61

Relationships
RelSci Relationships are individuals John J. Trizzino likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Chief Operating Officer at IMV, Inc.

Relationship likelihood: Strong

Former Executive Chairman at IMV, Inc.

Relationship likelihood: Strong

Chief Financial Officer at Appili Therapeutics, Inc.

Relationship likelihood: Strong

Senior Vice President, CMC, Nanoflu at Novavax, Inc.

Relationship likelihood: Strong

Former President, Chief Executive Officer & Director at IMV, Inc.

Relationship likelihood: Strong

Vice President, Biostatistics at Novavax, Inc.

Relationship likelihood: Strong

Former Vice President Intellivax at Capital Portfolio Management LLC

Relationship likelihood: Strong

Executive Vice President, Chief Financial Officer & Treasurer at Novavax, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Non-Independent Director at Torrent Capital Ltd.

Relationship likelihood: Strong

President at Pirus Biological & Vaccine Consulting

Relationship likelihood: Strong

Paths to John J. Trizzino
Potential Connections via
Relationship Science
You
John J. Trizzino
Executive Vice President, Chief Commercial Officer & Chief Business Officer at Novavax, Inc.
Education
Bachelor of Science Degree

In its ninth decade of providing access to the American dream through excellence in higher education, LIU is a multicampus, diverse, doctoral institution of higher learning. One of the largest and most comprehensive private universities in the country, the University offers more than 575 undergraduate, graduate and doctoral degree programs and certificates, and educates over 24,000* students in degree-credit and continuing education programs in Brooklyn, Brookville (LIU Post), Brentwood, Riverhead, and Rockland and Westchester (LIU Hudson). Other academic units include LIU Pharmacy (the Arnold & Marie Schwartz College of Pharmacy and Health Sciences), which prepares students for successful careers in the fields of pharmacy and health care; LIU Global, which provides a wide range of study abroad options at overseas centers in China, Costa Rica and India, and through programs in Australia, Ecuador, Peru, Taiwan, Thailand and Turkey; and LIU Online, which harnesses the latest technology to offer online and blended programs. LIU’s 630 full-time faculty members provide outstanding instruction, which is supplemented by internships and cooperative education opportunities. The accomplishments of more than 186,000 living alumni are a testament to the success of its mission – providing the highest level of education to people from all walks of life. The institution also provides enrichment for students and the community through the world-class arts programming at LIU Tilles Center, NCAA Division I and II athletic teams and the nationally renowned George Polk Awards in journalism

Since its inception in 1900, New York University Stern School of Business has been in and of New York City. Founded as the School of Commerce, Finance, and Accounting, the School initially offered training to students for careers in commerce in the burgeoning financial markets of New York City. Today, located in the heart of Greenwich Village with a campus in Westchester, Stern is one of the nation’s premier management education schools and research centers with a broad portfolio of academic programs at the graduate and undergraduate levels. With its global partnerships and engagement in NYU’s global network university, today NYU Stern is not only in and of the city, but also in and of the world.

Career History
Vice President-Business Development
2004 - 2009

ID Biomedical Corp. develops gene-based disease testing and subunit vaccines. It conducts research, development, manufacturing, sales, and marketing from its facilities in Canada and in the United States. The company was founded in 1991 and is headquartered in Vancouver, Canada.

Vice President-Business Development
1997 - 2004

Henry Schein, Inc., a FORTUNE 500® company and a member of the NASDAQ 100® Index, is the largest provider of health care products and services to medical, dental, and veterinary office-based practitioners. The Company is one of Fortune Magazine's "World’s Most Admired Companies", and is ranked number 1 in its industry in social responsibility and global competitiveness. Now more than ever, health care providers require specialized products and services to operate their practices efficiently. We offer an extensive selection of dental supplies, medical supplies, pharmaceuticals, vaccines, equipment, software technology, and much more. Our portfolio of practice solutions is designed to support our customers and to successfully meet their business goals and achieve optimal patient satisfaction

Vice President-Vaccine Franchise
2006 - 2009

MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD.

Boards & Committees
Chief Executive Officer, Director
2011 - Prior

IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities. Its drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple phases 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma) where it has identified a predictive biomarker. The company was founded by Warwick Kimmins and Brian E. Lowe on May 18, 2007 and is headquartered in Dartmouth, Canada.

Director
Prior

Tech Council of Maryland, Inc. provides membership association services for technology and life science communities. The firm serves the advanced technology and biotechnology communities. The company was founded in 1986 and is headquartered in Rockville, MD.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by John J. Trizzino. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of John J. Trizzino's profile does not indicate a business or promotional relationship of any kind between RelSci and John J. Trizzino.